Keros Therapeutics (NASDAQ:KROS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Several other analysts have also recently commented on KROS. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Leerink Partners lowered their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Finally, Wells Fargo & Company dropped their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $10.69 on Friday. The stock has a fifty day moving average price of $10.62 and a 200 day moving average price of $12.29. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55. The company has a market cap of $211.98 million, a PE ratio of -2.89 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Analysts anticipate that Keros Therapeutics will post -5.12 earnings per share for the current fiscal year.

Insider Activity at Keros Therapeutics

In related news, Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director owned 9,767 shares in the company, valued at $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director owned 10,958 shares in the company, valued at $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock worth $89,994 over the last 90 days. Company insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently modified their holdings of the company. Financial Management Professionals Inc. purchased a new stake in Keros Therapeutics during the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd increased its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Keros Therapeutics during the 1st quarter worth $129,000. Finally, New York State Common Retirement Fund raised its stake in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.